Published Comprehensive Preclinical Research on SQZ® AAC Platform in Frontiers in ImmunologyContinued Investigational New Drug-Enabling Activities for SQZ® TAC Platform; Submission Expected in First Half of 2023 with Clinical Batches Intended to be Manufactured on the Company’s Point-of-Care SystemAnticipate Interim.